The role of interleukin-6 in malignant mesothelioma

摘要: Malignant mesothelioma (MM) still remains a dismal disease with median overall survival between 9-12 months. During the past decade since introduction of multi-folate antagonist, pemetrexed, there have been no significant advances in its systemic treatment, particularly novel therapeutics that exhibited varying degrees success other solid tumours. In recent years, pleiotropic proinflammatory cytokine, interleukin-6 (IL-6) has emerged as mediator pivotal processes such cell proliferation and chemoresistance within tumour microenvironment addition to clinical symptoms commonly witnessed this disease. This manuscript provides brief summary on pathophysiology management MM, followed by role IL-6 tumourigenesis rationale for utilising anti-IL-6 alongside standard chemotherapy targeted agents an attempt prolong survival.